"Promising Results: Latest PoC studies showed evidence of complete regression of TNBC tumours and ongoing protective immunity."
There are only 2 ASX listed companies that have achieved that at a pre-clinical stage. IMU and now IVX. I couldn't find any other international company or uni / institute having achieved something similar.
That's why I think it should be valued at 5c.
GLTA
IVX Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)